Newswise — A life-sized artificial human lung created at the Technion-Israel Institute of Technology is the first diagnostic tool for understanding in real time how tiny particles move and behave in the deepest part of the human lungs (alveolar tissue). The patented platform could provide a better understanding of the health risks associated with airborne pollution, and be used for the evaluation and design of drugs for the respiratory system. The results were published recently in Scientific Reports.
Inhaled particles (also known as aerosols) are tiny particles that can originate in nature, and from industrial and transportation sources, and which enter the lungs via inhalation. Although they are just a few microns in size, i.e. one hundredth of the size of a grain of sand – increased and prolonged exposure to these particles may interfere with the activity of the body’s organs (including neurons in the brain), and in some cases even lead to the onset of cancers (e.g. lungs).
“This is the first diagnostic tool that enables quantitative monitoring of the dynamics of aerosols at such small scales,” said lead researcher Professor Josue Sznitman, of the Faculty of Biomedical Engineering. “It gives us the ability to directly observe airborne particle trajectories and their patterns of deposition in the alveoli in real time.”
Monitoring the movement of aerosols in the respiratory system, and especially how they are deposited in alveolar tissue, has long posed a challenge for researchers. This is due in part to their tiny size, and because their movement is affected by airflow, gravity and other forces. Another factor that makes it hard to map the movement of aerosols is the complex structure of the alveolar tissue, which contains hundreds of millions of tiny air sacs interconnected by dense texture of narrow ducts. For this reason, it is impossible to study the movement of these particles in vivo, and researchers have had to rely on animal-models or computer simulations.
The walls of the artificial lung system provide a realistic simulation of a real human lung. They expand and contract, similar to the actual respiratory system, making it possible to understand the behavior of both ‘bad’ inhaled particles (pollution) and ‘good’ particles that are administered as medication to the alveoli. The model could also reduce the need for animal testing in the study of the respiratory system.
According to its designer and builder Dr. Rami Fishler, also of the Technion Faculty of Biomedical Engineering, “the model consists of technologies similar to those used to manufacture computer chips, and comprises a branched network of minute air ducts approximately one-tenth of a millimeter wide, with craters simulating the alveoli.”
The Technion-Israel Institute of Technology is a major source of the innovation and brainpower that drives the Israeli economy, and a key to Israel’s renown as the world’s “Start-Up Nation.” Its three Nobel Prize winners exemplify academic excellence. Technion people, ideas and inventions make immeasurable contributions to the world including life-saving medicine, sustainable energy, computer science, water conservation and nanotechnology. The Joan and Irwin Jacobs Technion-Cornell Institute is a vital component of Cornell Tech, and a model for graduate applied science education that is expected to transform New York City’s economy.
American Technion Society (ATS) donors provide critical support for the Technion—more than $2 billion since its inception in 1940. Based in New York City, the ATS and its network of supporters across the U.S. provide funds for scholarships, fellowships, faculty recruitment and chairs, research, buildings, laboratories, classrooms and dormitories, and more.